• 약학회지
• /
• 제37권5호
• /
• pp.442-452
• /
• 1993

Previous experimental and clinical investigations suggest a possible role of new nootropic drug, oxiracetam, in improving cognitive performances in patients affected by organic brain syndrome. In this study, the cognitive and behavioral effects of oxiracetam treatment in patients with clinical symptoms of organic brain syndrome were evaluated. Sixty-six patients were enrolled and assigned to either oxiracetam or placebo, according to a randomized, double-blind design between two patient-groups. Either oxiracetam or placebo was orally given bid for 8 weeks ; daily dose of oxiracetam was 1600mg. All the patients, enrolled in this study, were diagnosed as having mild to moderate cognitive dysfunction as defined by a baseline Mini Mental State ExaminationKorean version (MMSE-K) score between 14 and 25. The patients under-went, at baseline, 4 weeks and 8 weeks after, routine laboratory study (CBC, SMA12, U/A, EKG) and the following neuropsychological tests ; MMSE-K, modified Korean Wechsler Intelligence Scale(MKWIS), Nurses' Observation Scale for Geriatric patients(NOSGER). Fifteen patients of whom were dropped out or excluded from the analysis because of poor compliance or violation of the protocol. Fiftyone patients (aged 54~78 years, male 25, female 26) were analyzed (vascular dementia, 30 ; senile dementia of Alzheimer type, 9 ; mixed type, 5 ; other cause, 7). Statistical analysis of the data demonstrated that the two groups were comparable at baseline. At the end of each study period the oxiracetam group scored significantly better on the majority of the tests evaluating cognitive function, psychometricity and the improvement rating scale of subjective symptoms than placebo group, in which worsening trends or no changes were seen on the whole. No side effects were noted during oxiracetam treatment. The present study, showing positive clinical findings after oxiracetam therapy, confirmed that this drug can be useful pharmacological treatment in organic brain syndrome.

• 분석과학
• /
• 제23권6호
• /
• pp.587-594
• /
• 2010

완제품의 주성분인 옥시라세탐이 함유된 의약품의 시험법실시 계획서에 따른 시험이 적절히 진행되었는지 시험법의 검증여부를 하고 본 protocol이 완제품 중 옥시라세탐의 정량분석을 위한 HPLC 분석법의 타당성을 검증하기 위한 문서화된 절차를 제공하는 것을 목적으로 한다. 본 실험에서는 옥시라세탐 함량시험에 사용된 분석법에 대하여 시스템 적합성, 정밀성, 직선성, 범위, 정확도, 특이성, 정량한계, 검출한계에 대하여 확인하였다. 실험결과 시스템적합성에서 정밀도(RSD%) 0.127%이하, 이론단수 15081, tailing factor 0.49, 그리고 분리능 32.41을 나타내었고, 정밀도실험에서는 RSD% 0.359% 이하의 결과를 보였다. 그리고 직선성 실험에서는 상관계수($R^2$)가 1을 나타내었고, 정확도 실험에서는 recovery test로서 최소 98.4%, 최대 99.6%로 기준을 만족하였다. 검출한계는 0.1 mg/L이였으며, 정량한계는 0.5 mg/L이었다. 그리고 특이성 실험에 있어서도 기준을 만족하는 결과를 나타내어 옥시라세탐을 주성분으로 하는 완제의약품 시험법은 적합한 시험법임이 검증되었다.

• Journal of Pharmaceutical Investigation
• /
• 제34권3호
• /
• pp.215-222
• /
• 2004

The purpose of the present study was designed to evaluate the bioequivalence of two oxiracetam tablets, Neuromed tablet (Korea Drug Co., reference drug) and Neuracetam tablet (Sam Jin Pharmaceutical Co., test drug), according to the guidelines of Korea Food and Drug Administration (KFDA). Release of oxiracetam from the tablet in vitro was tested using KP VIII Apparatus II method with various dissolution media (pH 1.2, 4.0, 6.8 buffer solution and water). Twenty-four healthy volunteers, $23.7\;{\pm}\;2.4$ year in age and $68.9\;{\pm}\;6.2$ kg in body weight, were divided into two groups and a randomized $2{\times}2$ cross-over study was performed. After oral administration of a tablet containing 800 mg of oxiracetam, blood samples were taken at predetermined time intervals and concentrations of oxiracetam in plasma were determined using HPLC-MS-MS. The dissolution profiles of two formulations were very similar at all dissolution media. In addition, pharmacokinetic parameters such as $AUC_t$, $C_{max}$ and $T_{max}$ were calculated and ANOVA test was utilized for the statistical analysis of the parameters using logarithmically transformed $AUC_t$ and $C_{max}$ untransformed $T_{max}$. The results showed that the differences between two formulations based on the reference drug were 0.42%, 0.45% and -12.58% for $AUC_t$, $C_{max}$ and $T_{max}$, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals for the log transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., $log0.94{\sim}log1.06$ and $log0.90{\sim}log1.07$ for $AUC_t$, and $C_{max}$, respectively), indicating that Neuracetam tablet is bioequivalent to Neuromed tablet. The major pharmacokinetic parameters, $AUC_t$, and $C_{max}$ met the criteria set by KFDA for bioequivalence indicating that Neuracetam tablet is bioequivalent to Neuromed tablet.